DAX-0,03 % EUR/USD-0,17 % Gold-0,01 % Öl (Brent)+0,38 %

BioInvent Management's Shareholding after Completion of the Rights Issue

Nachrichtenquelle: Business Wire (engl.)
15.06.2015, 08:54  |  529   |   |   

Regulatory News:

BioInvent International AB (publ) (STO:BINV) has previously announced that members of BioInvent’s management and key personnel have, in addition to existing holdings, purchased subscription rights and subscribed for new shares corresponding to a total of 2.8 per cent of the shares offered in the rights issue completed in May 2015. Following the completion of the rights issue Management’s changes in shareholdings are presented.

Management's shareholding Before the rights issue Changes After the rights issue
Michael Oredsson, CEO 43,000 527,648 570,648
Björn Frendéus, Chief Scientific Officer 804 311,168 311,972
Per-Anders Johansson, SVP President, Technical Operations 250,300 - 250,300
Anna Wickenberg, VP Clinical Development 0 +231,34 231,348

To the editors:

About BioInvent

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of new drugs, and provide BioInvent with the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, and Xoma. More information is available at www.bioinvent.com.

This information was brought to you by Cision http://news.cision.com

Mehr zm Thema

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Weitere Nachrichten des Autors